Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancer

References

• Roehrborn C , Black L . The economic burden of prostate cancer. BJU Int. 2011; 108: 806–13.
   PubMed Web of Science ®Google Scholar
• Ferlay J , Parkin DM , Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46: 765–81.
   PubMed Web of Science ®Google Scholar
• Globocan. Fast stats. World Health Organization, International Agency for Research on Cancer. 2008. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf [cited 12 February 2013]..
   Google Scholar
• Drummond FJ , Carsin A-E , Sharp L , Comber H . Trends in prostate specific antigen testing in Ireland: Lessons from a country without guidelines. Ir J Med Sci. 2010; 179: 47–49.
   Web of Science ®Google Scholar
• Ferlay J , Shin HR , Bray F , Forman D , Mathers C , Parkin DM et al. . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893–917.
   PubMed Web of Science ®Google Scholar
• O'Lorcain P , Comber H . Prostate cancer mortality predictions for Ireland up to 2015. Eur J Cancer Prev. 2007; 16: 328–33.
   Web of Science ®Google Scholar
• Heidenreich A , Bellmunt J , Bolla M . EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011; 5: 61–71.
   Google Scholar
• Groot MT , Boeken Kruger CG , Pelger RC , Uyl-de Groot CA . Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003; 43: 226–32.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP . Current issues in cancer: cancer of the prostate. BMJ. 1994; 340: 780.
   Google Scholar
• Scher HI , Morris MJ , Basch E , Heller G . End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice. J Clin Oncol. 2011; 29: 3695–704.
   PubMed Web of Science ®Google Scholar
• Heidenreich A , Bastian PJ , Bellmunt J , Bolla M , Joniau S , Mason MD . Guidelines on prostate cancer. European Association of Urology, March 2013. http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf [cited 1 April 2014]..
   Google Scholar
• Barlev A , Song X , Ivanov B , Setty V , Chung K . Payer costs for inpatient treatment for pathologic fracture, surgery to the bone and spinal cord compression among patient with multiple myeloma or bone metastasis. Am J Manag Care. 2010; 16: 693–702.
   Google Scholar
• Hagiwara M , Oglesby A , Chung K , Zilber S . The impact of bone metastases and skeletal related events on health care costs in prostate cancer patients receiving hormonal therapy. Community Oncol. 2011; 8: 508–15.
   Google Scholar
• Lage MJ , Barber BL , Harrison DJ , Jun S . The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008; 14: 317–22.
   PubMed Web of Science ®Google Scholar
• Mundy GR . Metastasis to the bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584–93.
   PubMed Web of Science ®Google Scholar
• de Bono JS , Oudard S , Ozguroglu M , Hansen S , Machiels JP , Kocak I et al. . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010; 376: 1147–54.
   PubMed Web of Science ®Google Scholar
• Botteman MF , Meijboom M , Foley I , Stephens JM , Chen YM , Kaura S . Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: Application to France, Germany, and the United Kingdom. Eur J Health Econ. 2011; 12: 575–88.
   PubMed Web of Science ®Google Scholar
• Djavan B , Nelson K , Kazzazi A , Bruhn A , Sadri H , Gomez-Pinillos A et al. . Immunotherapy in the treatment of advanced prostate cancer. Can J Urol. 2011; 18: 5865–74.
   Web of Science ®Google Scholar
• Weinfurt KP , Li Y , Castel LD , Saad F , Timbie JW , Glendenning GA et al. . The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005; 16: 579–84.
   PubMed Web of Science ®Google Scholar
• Sabbatini P , Larson SM , Kremer A , Zhang ZF , Sun M , Yeung H et al. . Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 948–57.
   PubMed Web of Science ®Google Scholar
• National Casemix Pogramme of the Health Services Executive. Ready reckoner of acute hospital inpatient and daycase activity & costs (Summarised by DRG) relating to 2010 costs & activities. National Casemix Programme. 2012. Available from: http://www.hse.ie/eng/services/Publications/ [cited 10 March 2013]..
   Google Scholar
• Mousseau M . Mims Ireland. 2012; Dublin: David Kelly.
   Google Scholar
• Joint Formulary Committee. British National Formulary. 2012; BMJ Publishing Group Ltd. Available from: http://www.BNF.org [cited 10 March 2013]..
   Google Scholar
• Ryan M . Guidelines for the economic evaluation of health technologies in Ireland. 2010; Dublin: HIQA. Available from: http://www.hiqa.ie..
   Google Scholar
• June–July 2012. Expert Opinion: Consultation with Professor Frank Sullivan, Director, Prostate Cancer Institute, NUI Galway; Dr. Eugene Moylan, Consultant Medical Oncologist, Cork University Hospital; Dr. John Kennedy, Consultant Medical Oncologist, St. James's Hospital, Dublin; Dr. Ray McDermott, Consultant Medical Oncologist, St Vincent's University Hospital, Dublin.
   Google Scholar
• Félix J , Andreozzi V , Soares M , Borrego P , Gervásio H , Moreira A et al. . Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: Estimation for the Portuguese National Health System. Value Health. 2011; 14: 499–505.
   PubMed Web of Science ®Google Scholar
• Nalesnik JG , Mysliwiec AG , Canby-Hagino E . Anemia in men with advanced prostate cancer: Incidence, etiology, and treatment. Rev Urol. 2004; 6: 1–4.
   PubMedGoogle Scholar
• McKeown K , Haase T , Pratschke J , Twomey S , Donovan H , Engling F . Dying in hospital in Ireland: An assessment of the quality of care in the last week of life. Report 5, Final Synthesis Report. 2010; Dublin: Irish Hospice Foundation. Available from: http://epubs.rcsi.ie/cgi/viewcontent.cgi?article=1000&context=icubhrep [cited 1 April 2014]..
   Google Scholar
• NCRI Cancer in Ireland 2011: Annual report of the national cancer registry. Ireland: National Cancer Registry. Available from: http://www.ncri.ie/pubs/pubfiles/AnnualReport2011.pdf .
   Google Scholar
• Nørgaard M , Jensen AØ , Jacobsen JB , Cetin K , Fryzek JP , Sørensen HT et al. . Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184: 162–67.
   PubMed Web of Science ®Google Scholar
• Wiley M . Using HIPE data as a research and planning tool: Limitations and opportunities: A response. Irish J Med Sci. 2005; 174: 52–57.
   Web of Science ®Google Scholar
• Burns R , Walsh B , Sharp L , O'Neill C . Prostate cancer screening practices in the Republic of Ireland – The determinants of uptake. J Health Serv Res Policy. 2012; 17(4): 206–211.
   Web of Science ®Google Scholar
• Walsh B , Silles M , O'Neill C . The role of private medical insurance in socioeconomic inequalities in cancer screening uptake in the Republic of Ireland. Health Econ. 2012; 12: 1250–56.
   Google Scholar
• Sharp L , Timmons A . The financial impact of cancer diagnosis. 2010; Ireland: National Cancer Registry. Available from: http://www.ncri.ie/publications/research-reports/financial-impact-cancer-diagnosis [cited 14 April 2013]..
   Google Scholar
• Luengo-Fernandez R , Leal J , Gray A , Sullivan R . Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol. 2013; 14: 1165–74.
   PubMed Web of Science ®Google Scholar